Compare · NVO vs RIGL
NVO vs RIGL
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rigel Pharmaceuticals Inc. (RIGL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RIGL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 329.1x RIGL ($556.5M).
- Over the past year, NVO is down 45.7% and RIGL is up 37.7% - RIGL leads by 83.3 points.
- RIGL has been more active in the news (16 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 6 for RIGL).
- Company
- Novo Nordisk A/S
- Rigel Pharmaceuticals Inc.
- Price
- $41.01-4.51%
- $30.06+0.25%
- Market cap
- $183.15B
- $556.5M
- 1M return
- -10.44%
- +14.38%
- 1Y return
- -45.66%
- +37.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 8
- 16
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest RIGL
- EVP & Chief Financial Officer Schorno Dean L exercised 3,381 shares at a strike of $14.83 and covered exercise/tax liability with 928 shares, increasing direct ownership by 3% to 78,790 units (SEC Form 4)
- EVP, Chief Commercial Officer Santos David A covered exercise/tax liability with 874 shares, decreasing direct ownership by 1% to 61,996 units (SEC Form 4)
- EVP, Chief Medical Officer Rojkjaer Lisa covered exercise/tax liability with 850 shares, decreasing direct ownership by 2% to 34,003 units (SEC Form 4)
- CEO, President Rodriguez Raul R covered exercise/tax liability with 2,424 shares, decreasing direct ownership by 0.86% to 279,593 units (SEC Form 4)
- EVP, GC, CCO & Corp Sec Furey Raymond J. covered exercise/tax liability with 877 shares, decreasing direct ownership by 2% to 50,936 units (SEC Form 4)
- Director Ali-Jackson Kamil sold $72,925 worth of shares (2,500 units at $29.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 12,625 units (SEC Form 4)
- Rigel to Present at the Jefferies Global Healthcare Conference
- Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
- Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Wasman Jane was granted 5,750 shares, increasing direct ownership by 46% to 18,250 units (SEC Form 4)